DEDICA (Dose of HEparin During Coronary Angioplasty) Trial

• Status: Unknown status
• Trial end date: 2012-12-01
• Target enrollment: 0
• Participant gender: All

Summary

International guidelines support the use of a full-dose heparin (anticoagulants) during coronary intervention. However, a lower dose of heparin may be adequate, thanks to advances in angioplasty techniques and the widespread use of pretreatment with two antiplatelet agents.

Thus the investigators designed a study comparing safety and efficacy of standard dose heparin (100 UI/Kg) versus low-dose (50 UI/Kg) in patients undergoing coronary angioplasty who are on aspirin and clopidogrel at the time of the procedure.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: San Filippo Neri General Hospital
• Collaborator: University of Roma La Sapienza
• Treatments: Calcium heparin; Heparin

Criteria

Inclusion Criteria:

• Stable angina, unstable angina or Non-ST elevation myocardial infarction undergoing coronary angioplasty.

• Mandatory pretreatment with aspirin and clopidogrel

Exclusion Criteria:

• ST elevation myocardial infarction

• Coronary interventions with rotational atherectomy

• Coronary interventions on chronic total occlusions (CTO)